Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

PlexusDx vs Tablet Health

PlexusDx
Graded #158

Higher grade

vs+20.1
Tablet Health
Graded #495

Lower grade

The verdict

PlexusDx takes it — 67.7/100 to 47.6/100.

PlexusDx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PlexusDx (plexusdx.com) is a US GLP-1 telehealth platform offering compounded weight-loss medications with licensed providers in all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePlexusDx +29
74
45
Dose & formulationPlexusDx +13
64
51
Clinical oversightPlexusDx +37
74
37
Labs & monitoringPlexusDx +2
52
50
FulfillmentPlexusDx +21
78
57
Contract termsEven
55
55
PlexusDx · left barTablet Health · right bar

The numbers

MetricPlexusDxTablet Health
WeighScore67.7/10047.6/100
GradeCC
Scorecard rank#158#495
Semaglutide$149/mo (starting dose, compounded)Not disclosed
Tirzepatide$249/mo (starting dose, compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
PlexusDx

Graded #158 · C

Strengths

  • Licensed providers available in all 50 states
  • Range of options including low-cost microdose GLP-1 from $129/mo
  • Optional Precision Peptide genetic panel adds a personalization angle
  • Independent clinician review via state-licensed telehealth platform
  • Compounded medications from state-licensed pharmacies

Where it loses points

  • Compounded medications only; no FDA-approved brand options
  • Specific compounding pharmacies not named
  • Genetic-panel upsell may not add clinical value for everyone
  • Tirzepatide pricing from $249/mo is higher than budget rivals
  • No insurance accepted
Tablet Health

Graded #495 · C

Strengths

  • LegitScript Certified
  • Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
  • Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
  • Mid-tier pricing starting $179–$299/mo across all four product variants
  • No commitment — cancel anytime

Where it loses points

  • States served not published — you must complete the intake quiz to learn eligibility
  • No founder, CEO, medical director, or pharmacist-in-charge named anywhere
  • No BBB profile found
  • Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard